NASDAQ : MGRX
Mangoceuticals, Inc. — Key statistics
Healthcare · Health Information Services · United States
Last price 0.2543 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.65M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.19M |
| Enterprise Value | 5.24M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 22.22M |
| Shares Outstanding | 22.22M |
| Shares Change (YoY) | +208.91% |
| Shares Change (QoQ) | +3.87% |
| Owned by Insiders (%) | 22.38% |
| Owned by Institutions (%) | 5.60% |
| Float | 16.28M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.46 |
| Forward PS | n/a |
| PB Ratio | 0.34 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 16.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.18 |
| Quick Ratio | 0.16 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.17 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -95.10% |
| Return on Assets (ROA) | -46.97% |
| Return on Invested Capital (ROIC) | -50.33% |
| Return on Capital Employed (ROCE) | -102.99% |
| Weighted Average Cost of Capital (WACC) | 23.80% |
| Revenue Per Employee | $105,076 |
| Profits Per Employee | -$5.43M |
| Employee Count | 3 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.98 |
| 52-Week Price Change | -89.29% |
| 50-Day Moving Average | 0.38 |
| 200-Day Moving Average | 0.41 |
| Relative Strength Index (RSI) | 31.70 |
| Average Volume (20 Days) | 464,333 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 91,564 |
| Short Previous Month | 438,786 |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.56% |
| Short Ratio (days to cover) | 0.13 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 315,227 |
| Gross Profit | 171,590 |
| Operating Income | -13.16M |
| Pretax Income | -15.10M |
| Net Income | -16.28M |
| EBITDA | -12.10M |
| EBIT | -13.16M |
| Loss Per Share | -$1.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 228,688 |
| Total Debt | 279,207 |
| Net Cash | -50,519 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | 12.52M |
| Book Value Per Share | 0.70 |
| Working Capital | -1.15M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -3.89M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.06M |
| Net Borrowing | -86,556 |
| Free Cash Flow | -3.89M |
| FCF Per Share | -$0.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | 54.43% |
| Operating Margin | -4,173.65% |
| Pretax Margin | -4,791.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -208.91% |
| Shareholder Yield | -208.91% |
| Earnings Yield | -470.29% |
| FCF Yield | -75.01% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.59 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |